Pharmaresearch Bio Co (XKRX:217950) Change In Working Capital : ₩-554 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co Change In Working Capital?

Pharmaresearch Bio Co's change in working capital for the quarter that ended in Dec. 2023 was ₩-554 Mil.

Pharmaresearch Bio Co's change in working capital for the fiscal year that ended in Dec. 2023 was ₩-554 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Pharmaresearch Bio Co Change In Working Capital Historical Data

The historical data trend for Pharmaresearch Bio Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co Change In Working Capital Chart

Pharmaresearch Bio Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-2,208.55

116.28

359.88

-958.15

-553.85

Pharmaresearch Bio Co Semi-Annual Data
	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Change In Working Capital	Get a 7-Day Free Trial			-2,208.55	116.28	359.88	-958.15	-553.85

Pharmaresearch Bio Co Change In Working Capital Calculation

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-554 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Pharmaresearch Bio Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmaresearch Bio Co (XKRX:217950) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494

Website

http://www.pr-bio.co.kr

Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co (XKRX:217950) Headlines

No Headlines